SUBSCRIBE
SUBSCRIBE

Phase I

Drug Development
Medicago Kicks Off Phase I Trial for Plant-Derived COVID-19 Vaccine Candidate
It has already administered the first doses of the candidate in healthy human subjects, and the company intends to initiate a Phase II/III trial this coming October.
July 14, 2020
 · 
3 min read
 · 
Krystle Vermes
Policy
Biopharma Update on the Novel Coronavirus: July 15
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for July 15, 2020.
July 14, 2020
 · 
5 min read
 · 
BioSpace Editorial Staff
Drug Development
Biopharma Update on the Novel Coronavirus: July 13
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for July 13, 2020.
July 13, 2020
 · 
3 min read
 · 
BioSpace Editorial Staff
Drug Development
Biogen Shares Positive Data on Phase I/II Trial of Tofersen for SOD1-ALS
Biogen announced on Wednesday that it has seen positive results from its Phase I/II study of tofersen, also known as BIIB067, for the treatment of superoxide dismutase 1 (SOD1) amyotrophic lateral sclerosis (ALS).
July 10, 2020
 · 
3 min read
 · 
Krystle Vermes
Drug Development
Clinical Catch-Up: July 6-10
Everybody seems to be back to work after the U.S. 4th of July holiday. Here’s a look at last week’s clinical trial updates.
July 10, 2020
 · 
10 min read
 · 
Mark Terry
Policy
Biopharma Update on the Novel Coronavirus: July 10
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for July 10, 2020.
July 9, 2020
 · 
4 min read
 · 
BioSpace Editorial Staff
Drug Development
NIAID Creates Clinical Trials Network to Focus on COVID-19 Vaccines, Monoclonal Antibodies
The National Institute of Allergy & Infectious Diseases (NIAID) has founded a new clinical trials network focused on enrolling volunteers in clinical trials for COVID-19 vaccines and monoclonal antibodies.
July 9, 2020
 · 
3 min read
 · 
Mark Terry
Policy
Biopharma Update on the Novel Coronavirus: July 8
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for July 8, 2020.
July 7, 2020
 · 
5 min read
 · 
BioSpace Editorial Staff
Drug Development
Cellectis’ CAR-T Trial for Multiple Myeloma on Clinical Hold After Patient Death
Cellectis, based in Paris and New York, announced that the U.S. Food and Drug Administration (FDA) had placed a clinical hold on its MELANI-01 trial.
July 7, 2020
 · 
3 min read
 · 
Mark Terry
Policy
Biopharma Update on the Novel Coronavirus: July 6
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for July 6, 2020.
July 6, 2020
 · 
2 min read
 · 
BioSpace Editorial Staff
Load More
PRESS RELEASES
Drug Development
Corbus Announces Dosing of First Patient in U.S. Phase 1 Clinical Trial of Its Next Generation Nectin-4 Targeting ADC
April 2, 2024
 · 
4 min read
Drug Development
Surrozen Announces Safety, Pharmacodynamic and Liver Function Data for SZN-043
April 1, 2024
 · 
9 min read
Drug Development
Equillium Announces Positive Topline Data from the Type B Portion of the Phase 1b EQUALISE Study of Itolizumab in Lupus Nephritis
April 1, 2024
 · 
9 min read
Drug Development
Context Therapeutics Submits IND Application to Evaluate CTIM-76 in Claudin 6-Positive Cancers
April 1, 2024
 · 
4 min read
Drug Development
PassPort Technologies, Inc. Announces Positive Interim Phase I Results of Zolmitriptan Transdermal Microporation System for the Treatment of Acute Migraine
March 29, 2024
 · 
3 min read
Drug Development
InnoCare Announces Dosing of First Patient in Clinical Study of the Combination of SHP2 Inhibitor ICP-189 and EGFR Inhibitor Furmonertinib
March 28, 2024
 · 
3 min read
Drug Development
Candel Therapeutics Announces Oral Presentation During the 5th Glioblastoma Drug Development Summit with Update on Phase 1b Clinical Trial of CAN-3110 in Recurrent High-Grade Glioma
March 28, 2024
 · 
8 min read
Drug Development
MAPLIGHT THERAPEUTICS ANNOUNCES INITIATION OF PHASE 1 CLINICAL TRIAL FOR ML-007/PAC, UNDER DEVELOPMENT FOR SCHIZOPHRENIA AND ALZHEIMER’S DISEASE PSYCHOSIS
March 28, 2024
 · 
4 min read
Drug Development
AEOVIAN PHARMACEUTICALS DOSES FIRST PARTICIPANTS IN PHASE 1 CLINICAL TRIAL, STRENGTHENS LEADERSHIP TEAM AND RAISES ADDITIONAL $50 MILLION FINANCING
March 28, 2024
 · 
6 min read
Drug Development
Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating Effects of NBI-1065890, a Second-Generation VMAT2 Inhibitor, in Healthy Adults
March 28, 2024
 · 
4 min read
Drug Development
Aurion Biotech Announces First Canadian Subject Dosed in Phase 1 / 2 Clinical Trial
March 28, 2024
 · 
3 min read
Drug Development
Azura Ophthalmics to Present New Data Supporting the Potential of AZR-MD-001 to be the First Ophthalmic Keratolytic for Ocular Surface Diseases
March 28, 2024
 · 
9 min read
Drug Development
Ocean Biomedical (NASDAQ: OCEA) Congratulates JV Partner, Virion Therapeutics, on Promising First-Ever Human Phase 1B Clinical Safety Data for Their Lead Checkpoint Modifier-Containing Immunotherapy for HBV Functional Cure, at Global APASL
March 28, 2024
 · 
8 min read
Drug Development
REGENXBIO Announces Lancet Publication of Phase I/IIa Study Evaluating ABBV-RGX-314 as a One-Time Gene Therapy for Wet AMD
March 28, 2024
 · 
8 min read
Business
Gilead and Xilio Announce Exclusive License Agreement for Tumor-Activated IL-12 Program
March 28, 2024
 · 
10 min read
Drug Development
Affimed Reports 2023 Financial Results and Operational Progress
March 28, 2024
 · 
15 min read
Drug Development
Zura Bio Reports Full Year 2023 Financial Results, Business Highlights, and Appoints Robert Lisicki as Chief Executive Officer
March 28, 2024
 · 
12 min read
Drug Development
Promising First-In-Human Phase 1B Clinical Study Data from VRON-0200, a Novel, First-in-Class Checkpoint Modifier Immunotherapy for Chronic Hepatitis B Virus Functional Cure, Presented as Late-Breaker at 2024 APASL Global Liver Meeting
March 27, 2024
 · 
5 min read
Drug Development
Sagimet Biosciences Announces Completion of Phase 1 Hepatic Impairment Study with FASN Inhibitor Denifanstat
March 27, 2024
 · 
5 min read
Drug Development
Iambic Therapeutics Announces First Patient Dosed in Phase 1 Clinical Study of IAM1363, a Highly Selective HER2 Inhibitor for the Treatment of Solid Tumors
March 27, 2024
 · 
3 min read
Load More